Viewpoint Molecular Targeting, Inc. develops pharmaceutical drugs for diagnostic imaging and therapy for cancer, with a focus on metastatic melanoma and neuroendocrine tumors. Our novel image-guided therapies enable a personalized approach to select patients that can benefit most and to optimize treatment planning for our targeted therapies. Our unique “theranostic” agents possess properties for both diagnostic imaging and therapy for cancer, personalizing the selection of patients and optimizing patient care.
Our current products are focused on image-guided therapy for metastatic melanoma and combine discovery of new melanoma specific cancer cell targets and the development of highly specific ligands for those targets with state-of-the-art molecular imaging technologies, such as single photon emission computed tomography (SPECT) and positron emission tomography (PET). Our lead product targets a cell surface receptor that is found in high concentrations on the cell surface of metastatic melanoma cells, while being virtually absent on most other cells and tissues in the body. The specificity of our targeting ligand for this molecular target directs our imaging and therapy agent specifically to metastatic melanoma cells, singling them out for diagnostic imaging and delivery of therapy directly to the microenvironment of melanoma disease. We have invented or license a portfolio of theranostics at the preclinical and clinical stage of development, with our lead agent poised for Phase I human imaging of metastatic melanoma.
Our vision is to be the global leader in the development of personalized image-guided personalized therapy solutions to improve treatment and quality of life for cancer patients. We are committed to discovery of new molecular targets that are specific to metastatic melanoma and cancer and to developing next generation highly specific targeting ligands that bind with high affinity and specificity to these molecular markers of disease. We are further committed to accelerating the translation of these discoveries to relevant image-guided therapies and safely advancing these discoveries to human clinical trials that give physicians new and better options for melanoma patient care with fewer side effects and better outcomes.
Viewpoint operates at locations in Iowa City, IA near the University of Iowa, which serves as a discovery engine for our technologies.